Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model

Neurobiology of Aging

Volumn 35, Issue 12, 2014, Pages 2736-2745

  Zhao, Lei ^a   Gong, Neng ^b   Liu, Meng ^a   Pan, Xiaoli ^a   Sang, Shaoming ^a   Sun, Xiaojing ^a   Yu, Zhe ^b   Fang, Qi ^b   Zhao, Na ^a   Fei, Guoqiang ^a   Jin, Lirong ^a   Zhong, Chunjiu ^a   Xu, Tianle ^b  

^a FUDAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Alzheimer's disease; Glycogen synthase kinase 3; Lithium; Pyrroloquinoline quinone; Amyloid binding alcohol dehydrogenase

Indexed keywords

ALCOHOL DEHYDROGENASE; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DONEPEZIL; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; LITHIUM DERIVATIVE; PRESENILIN 1; TAU PROTEIN; TRILITHIUM PYRROLOQUINOLINEQUINONE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; ANTIOXIDANT; PYRROLE DERIVATIVE; PYRROLOQUINOLINE; QUINOLINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; LEARNING; LONG TERM POTENTIATION; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; MEMORY; METABOLISM; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLYCOGEN SYNTHASE KINASE 3; LEARNING; LITHIUM COMPOUNDS; LONG-TERM POTENTIATION; MEMORY; MICE, TRANSGENIC; PYRROLES; QUINOLINES; TAU PROTEINS;

EID: 84911439045     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.06.003     Document Type: Article

References (31)

1. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 2002, 4:153-165.
2. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
3. Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
4. Castellani R.J., Smith M.A. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J.Pathol. 2011, 224:147-152.
5. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108:21-43.
6. Chowanadisai W., Bauerly K.A., Tchaparian E., Wong A., Cortopassi G.A., Rucker R.B. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J.B. Chem. 2010, 285:142-152.
7. Forlenza O.V., Diniz B.S., Radanovic M., Santos F.S., Talib L.L., Gattaz W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry 2011, 198:351-356.
8. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
9. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
10. He K., Nukada H., Urakami T., Murphy M.P. Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ): implications for its function in biological systems. Biochem. Pharmacol. 2003, 65:67-74.
11. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
12. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J.B. Chem. 1997, 272:25326-25332.
13. Kasahara T., Kato T. Nutritional biochemistry: a new redox-cofactor vitamin for mammals. Nature 2003, 422:832.
14. Kessing L.V., Sondergard L., Forman J.L., Andersen P.K. Lithium treatment and risk of dementia. Arch. Gen. Psychiatry 2008, 65:1331-1335.
15. Kessing L.V., Forman J.L., Andersen P.K. Does lithium protect against dementia?. Bipolar Disord. 2010, 12:87-94.
16. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
17. Misra H.S., Khairnar N.P., Barik A., Indira Priyadarsini K., Mohan H., Apte S.K. Pyrroloquinoline-quinone: a reactive oxygen species scavenger in bacteria. FEBS Lett. 2004, 578:26-30.
18. Misra H.S., Rajpurohit Y.S., Khairnar N.P. Pyrroloquinoline-quinone and its versatile roles in biological processes. J.Biosci. 2012, 37:313-325.
19. Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br. J. Psychiatry 2007, 190:359-360.
20. Nunes M.A., Viel T.A., Buck H.S. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr. Alzheimer Res. 2013, 10:104-107.
21. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
22. Pan X., Gong N., Zhao J., Yu Z., Gu F., Chen J., Sun X., Zhao L., Yu M., Xu Z., Dong W., Qin Y., Fei G., Zhong C., Xu T.L. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133:1342-1351.
23. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
24. Pilcher H.R. Drug research: the ups and downs of lithium. Nature 2003, 425:118-120.
25. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., Crews L., Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J.Neurosci. 2007, 27:1981-1991.
26. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
27. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
28. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
29. Terao T., Nakano H., Inoue Y., Okamoto T., Nakamura J., Iwata N. Lithium and dementia: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1125-1128.
30. Yao J., Du H., Yan S., Fang F., Wang C., Lue L.F., Guo L., Chen D., Stern D.M., Gunn Moore F.J., Xi Chen J., Arancio O., Yan S.S. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J.Neurosci. 2011, 31:2313-2320.
31. Zhao N., Zhong C., Wang Y., Zhao Y., Gong N., Zhou G., Xu T., Hong Z. Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol. Dis. 2008, 29:176-185.